Search Results

Catheter Precision, Inc., a US based innovative medical device company announced that it has received its first purchase order from Qatar.

Catheter Precision, Inc. a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product, releases Q1 Financials, Operational Report for the quarter ending March 31, 2024.

Catheter Precision, Inc announced that VIVO was used for the first time on a pediatric patient in Turkey.

Catheter Precision, Inc., a US based medical device company focused on electrophysiology products, is honored to be sponsor a session at the upcoming Monaco USA Arrhythmia Course taking place March 21-23 in Monaco.

Catheter Precision, Inc is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024.

Catheter Precision, Inc. announced corporate highlights of the third quarter of 2023.

Catheter Precision, Inc. announced that Great Britain and the European Market have allowed two new patents, further strengthening the company’s IP position for its LockeT product line.

Thubrikar Aortic Valve, Inc. today announced successful results in the first two patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) using the new Precision 2™ Delivery Catheter. Interventional Cardiologist and TAVI-1 Study Principal Investigator, Jaroslaw Trebacz, MD, performed the procedures at the John Paul II Hospital in Krakow, Poland.